Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06609460 · ClinicalTrials.gov registry record · Phase 2
Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
A Phase 2 study of Influenza, sponsored by Cidara Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 5,071
- Enrollment target
- 20
- Study locations
NCT06609460 is a Phase 2 study of Influenza that has completed, run by Cidara Therapeutics. The registered enrollment target is 5,071 participants, below the 36,771-participant average among 156 other Influenza trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT06609460, a Phase 2 study of Influenza, has completed, sponsored by Cidara Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5,071 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness of CD388 in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, and to select a dose of CD388 that is effective in preventing the same, when administered as a single dose via 3 subcutaneous (SQ) injections to adult participants in stable health, and to evaluate the safety and tolerability of CD388, as compared to placebo.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT CD388 Injection
Study Locations (20)
Florida
- Alliance for Multispecialty Research, LLC - Fort Myers
- Nature Coast Clinical Research - Inverness
- Health Awareness, LLC - Jupiter
- South Florida Research Center, Inc. - Miami
- Clinical Site Partners, LLC dba Flourish Research - Miami
- Floridian Clinical Research - Miami Lakes
- Healthcare Clinical Data, Inc. - North Miami
California
- Velocity Clinical Research - Huntington Park - Huntington Park
- Velocity Clinical Research - San Diego - La Mesa
- Catalina Research Institute, LLC - Montclair
- Profound Research LLC - Oceanside
- Acclaim Clinical Research - San Diego
Alabama
- Pinnacle Research Group, LLC - Anniston
- Cullman Clinical Trials - Cullman
Arizona
- Fiel Family and Sports Medicine/CCT Research - Tempe
- Del Sol Research Management, LLC - Tucson
Colorado
- Lynn Institute of the Rockies - Colorado Springs
- Critical Care, Pulmonary & Sleep Associates, PLLP/CCT Research - Lakewood
Arkansas
- Baptist Health Center for Clinical Research - Little Rock
Georgia
- DelRicht Research - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,071 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2025-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06609460
The ClinicalTrials.gov registry entry for NCT06609460 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5,071 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,771-participant average among 156 other Influenza trials with a reported enrollment target (86% lower). The listed sponsor is Cidara Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06609460 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06609460 about?
NCT06609460 is a clinical study titled "Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications". The purpose of this study is to evaluate the effectiveness of CD388 in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, and to select a dose of CD388 that is effective in preventing the same, when administered as a single dose via 3 subcutaneous (SQ) injectio...
What is the current status of trial NCT06609460?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5,071 participants. The study started on 2024-09-20. Estimated completion is 2025-09-19.
What conditions does trial NCT06609460 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT06609460?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), CD388 Injection (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06609460?
This trial is sponsored by Cidara Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06609460 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
RECRUITING · Phase 2
-
Systems Investigation of Vaccine Responses in Aging and Frailty
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.